8-K: Celularity Secures Loan Forbearance Agreements and Plans Public Offering to Address Debt

Celularity Inc. has entered into binding term sheets with Resorts World Inc Pte Ltd (RWI) and C.V. Starr & Co., Inc. (Starr) to extend forbearance agreements and loan maturities, contingent on a future public offering.

Summary

• Celularity Inc. has entered into binding term sheets with RWI and Starr to extend forbearance agreements on existing loans.
• The agreements involve extending the maturity dates of the RWI and Starr loans to February 15, 2026.
• As part of the agreements, Celularity plans to use proceeds from its next registered public offering to pay approximately $1.3 million to RWI and $0.8 million to Starr, representing unpaid cash interest.
• Celularity will issue new warrants to RWI for 500,000 shares and to Starr for 100,000 shares of Class A common stock.
• The exercise prices of existing warrants held by RWI and Starr will be re-priced based on the closing price of Celularity's Class A common stock on July 24, 2025, subject to certain conditions and floors.
• The RWI loans consist of an initial loan of $6,000,000, a second loan of $6,000,000, and a third loan of $15,000,000, net of an original issue discount of $3,750,000.
• The Starr Loan is in the aggregate principal amount of $5,000,000, net of an original issue discount amount equal to $100,000.

Sentiment

Score: 4

Explanation: The announcement is mixed. While securing forbearance agreements is positive, the reliance on a future public offering and the existing debt burden raise concerns. The sentiment is cautiously negative.

Positives

• Securing forbearance agreements provides Celularity with additional time to address its debt obligations.
• The planned public offering could provide the company with necessary capital to repay interest and potentially fund operations.
• The re-pricing of warrants could incentivize warrant holders if the company's stock performs well.
• Extending the maturity dates of the loans to February 15, 2026 provides Celularity with more financial flexibility.

Negatives

• The company is relying on a future public offering to meet its debt obligations, which is subject to market conditions and investor interest.
• The issuance of new warrants could dilute existing shareholders.
• The company has not paid cash interest due on the RWI Loans and the Starr Loan through January 31, 2025.
• The RWI Loans include an original issue discount amount equal to $3,750,000.
• The Starr Loan includes an original issue discount amount equal to $100,000.

Risks

• Failure to successfully complete a public offering could jeopardize the forbearance agreements and the company's ability to meet its debt obligations.
• The re-pricing of warrants may not be favorable to the company if the stock price does not increase.
• Continued reliance on debt financing could negatively impact the company's financial stability.
• Market conditions and investor sentiment could impact the success of the planned public offering.

Future Outlook

Celularity intends to use proceeds from its next registered public offering to pay outstanding interest to RWI and Starr and extend the maturity dates of the loans.

Industry Context

In the biotechnology industry, securing funding and managing debt are critical for companies like Celularity, especially those in the clinical stage. Forbearance agreements and loan extensions are common strategies to navigate financial challenges and maintain operational flexibility. The planned public offering reflects a broader trend of biotech companies seeking capital through public markets to fund research, development, and commercialization efforts.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector often utilize debt financing and equity offerings to fund operations and research.
• Loan forbearance agreements are a common tool for companies facing short-term financial difficulties, allowing them to negotiate more favorable terms with lenders.
• The issuance of warrants is a typical incentive for lenders in high-risk situations, providing them with potential upside if the company's stock performs well.
• Repricing warrants is a common practice to maintain the incentive for warrant holders when the stock price has declined.

Stakeholder Impact

• Shareholders may experience dilution if the public offering and warrant issuances are completed.
• Employees' job security could be affected by the company's financial stability.
• Creditors' confidence in the company's ability to repay debt may be impacted.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• Celularity needs to successfully execute a registered public offering.
• The company must enter into amendments with RWI and Starr to finalize the loan extensions.
• The company needs to issue new warrants to RWI and Starr.
• The company needs to reprice existing warrants held by RWI and Starr on July 24, 2025.

Key Dates

Keywords

Celularity, forbearance agreement, loan extension, public offering, warrants, debt, RWI, Starr